Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Survivors who stop taking aspirin increase risk of another stroke

03.02.2005


American Stroke Association meeting report



Stroke survivors who stopped taking their prescribed daily aspirin tripled their risk of having another stroke within the month, according to research presented today at the American Stroke Association’s International Stroke Conference 2005. "This is the first controlled retrospective study to investigate the potential risk of suffering ischemic stroke shortly after discontinuing aspirin," said Patrik Michel, M.D., co-author of the study and director of the acute stroke unit at Lausanne University Hospital in Lausanne, Switzerland.

The results confirm and extend previous observations in stroke survivors who stopped taking aspirin. Aspirin is the most often prescribed medication to prevent a recurrent stroke or heart attack, Michel said. This study reinforces the importance of compliance with aspirin therapy in patients with symptomatic atherosclerosis, including previous stroke. Patients and physicians should be aware of a possible increased risk of stroke when aspirin is stopped.


Researchers selected 309 patients who had a stroke or transient ischemic attack (TIA) and were on long-term aspirin therapy for secondary prevention of heart attack and stroke. They matched these patients with 309 control patients who had a stroke or TIA more than six months before and were also taking long-term aspirin therapy.

The average age of the entire study population was 71 years, and 62 percent were men. In each group about 69 percent had hypertension, 20 percent had diabetes, and 14 percent were smokers. In the study group, 52 percent had dyslipidemia compared to 58 percent in the control group (not statistically significant). In the study group, 36 percent had coronary heart disease compared to 18 percent in the control group (a statistically significant difference). Also, a similar number of patients in both groups were taking either a 100 mg or 300 mg dosage of aspirin.

Researchers found that 13 patients in the stroke group had discontinued aspirin within four weeks before their stroke, while only four patients did in the control group. Therefore, patients with stroke or TIA were 3.25 times more likely to have interrupted their aspirin than patients with similar risk factors but no new stroke or TIA. Seventy-seven percent of the ischemic strokes related to aspirin discontinuation occurred in the first eight days after aspirin was stopped; the other 23 percent occurred from day nine to 30.

"Although the absolute risk of suffering a substantial stroke during a short period of aspirin discontinuation is probably not very high, this difference is meaningful, and patients and physicians should be informed about this potential risk," Michel said.

About one-third of patients in the study group discontinued aspirin themselves because of minor bleeding or lack of compliance. In about two-thirds of patients, physicians had ordered aspirin discontinuation for minor bleeding or minor surgical procedures.

The current literature suggests that many diagnostic or surgical procedures, such as cataract surgery or dermatological procedures, may be safely performed while the patient is taking low-dose aspirin.

Michel said a prospective, controlled, randomized trial should be conducted to prove exactly what the stroke risk is from discontinuing aspirin use. He said that such a trial should be a cooperative effort between neurologists, general practitioners, and sub-specialists doing diagnostic and surgical procedures for which aspirin is often discontinued.

Lead author on the study is Alexandre Maulaz, M.D. Other co-authors are Daniel Bezerra, M.D.; Bartolomeij Piechowski-Joywiak, M.D.; and Julien Bogousslavsky, M.D.

Carole Bullock | EurekAlert!
Further information:
http://www.heart.org

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>